SynAct Pharma

SynAct Pharma

Sweden - Lund
Pharmaceutical

Focus: Small Molecule Targeting Inflammation without Immunosuppression

SynAct Pharma is a life sciences company focused on Small Molecule Targeting Inflammation without Immunosuppression.

Immunology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Phase 2
Clinical Trials (1)
NCT06671054A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Phase 2
Clinical Trials (1)
NCT04456816A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
Phase 2
Phase 2
Clinical Trials (1)
NCT05604885A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Phase 2
Phase 2
Clinical Trials (1)
NCT04004429A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Phase 2
Phase 2
Clinical Trials (1)
NCT05516979A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 5 clinical trials
Top TAs: Immunology, Nephrology
Publications: 2 in PubMed
Therapeutic Area Focus
Immunology
4 pipeline
Nephrology
1 pipeline
Marketed
Pipeline